Literature DB >> 14765315

Botulinum toxin injection after biliary sphincterotomy.

A Gorelick1, J Barnett, W Chey, M Anderson, G Elta.   

Abstract

BACKGROUND AND STUDY AIMS: Endoscopic biliary sphincterotomy in patients with sphincter of Oddi dysfunction (SOD) is associated with a high risk of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP), which may be secondary to residual pancreatic sphincter hypertension. It was hypothesized that botulinum toxin injection could be used to reduce pancreatic sphincter hypertension temporarily in SOD patients after biliary sphincterotomy, thereby reducing the rate of procedure-induced pancreatitis. PATIENTS AND METHODS: All patients undergoing ERCP with manometry due to a suspected biliary SOD were asked to participate in the study. Patients with elevated basal sphincter pressures were randomly assigned to receive either botulinum toxin or a sham saline injection after biliary sphincterotomy. Fifty units of botulinum toxin were delivered via a sclerotherapy needle in the form of two 25-U injections of 0.25 ml each into the pancreatic sphincter. In patients in the sham arm, 0.50 ml of saline was injected into the duodenal lumen.
RESULTS: Between 12 February 1999 and 29 November 2000, a total of 98 patients were referred for ERCP with manometry; 86 consented to participate in the study, and 26 had elevated baseline pressures and underwent random assignment. Twelve received botulinum toxin injection and 14 were randomly assigned to receive the sham injection. A total of six patients in the sham group (43 %) developed procedure-induced pancreatitis, compared with three patients in the botulinum toxin group (25 %; P = 0.34).
CONCLUSIONS: Biliary sphincterotomy in patients with sphincter of Oddi dysfunction without pancreatic protection is risky and should no longer be carried out. This study demonstrates that botulinum toxin injection into the residual pancreatic sphincter after biliary sphincterotomy is technically feasible and safe, showing a trend toward a reduced post-ERCP pancreatitis rate in patients with sphincter of Oddi dysfunction. Further studies will need to confirm the validity of these experimental results before this technique can be used routinely.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14765315     DOI: 10.1055/s-2004-814185

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  10 in total

Review 1.  Randomized sham-controlled trials in endoscopy: a systematic review and meta-analysis of adverse events.

Authors:  Allison R Schulman; Violeta Popov; Christopher C Thompson
Journal:  Gastrointest Endosc       Date:  2017-08-09       Impact factor: 9.427

Review 2.  Sphincter of Oddi dysfunction: managing the patient with chronic biliary pain.

Authors:  Lana Bistritz; Vincent G Bain
Journal:  World J Gastroenterol       Date:  2006-06-28       Impact factor: 5.742

3.  Can patient and pain characteristics predict manometric sphincter of Oddi dysfunction in patients with clinically suspected sphincter of Oddi dysfunction?

Authors:  Joseph Romagnuolo; Peter B Cotton; Valerie Durkalski; Qi Pauls; Olga Brawman-Mintzer; Douglas A Drossman; Patrick Mauldin; Kyle Orrell; April W Williams; Evan L Fogel; Paul R Tarnasky; Giuseppe Aliperti; Martin L Freeman; Richard A Kozarek; Priya A Jamidar; C Mel Wilcox; Jose Serrano; Grace H Elta
Journal:  Gastrointest Endosc       Date:  2014-01-25       Impact factor: 9.427

4.  Gastrointestinal Uses of Botulinum Toxin.

Authors:  Maria Cariati; Maria Michela Chiarello; Marco Cannistra'; Maria Antonietta Lerose; Giuseppe Brisinda
Journal:  Handb Exp Pharmacol       Date:  2021

5.  Botulinum toxin and gastrointestinal tract disorders: panacea, placebo, or pathway to the future?

Authors:  Brian E Lacy; Kirsten Weiser; Abigail Kennedy
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-04

Review 6.  The diagnosis and management of Sphincter of Oddi dysfunction: a systematic review.

Authors:  Thomas C Hall; Ashley R Dennison; Giuseppe Garcea
Journal:  Langenbecks Arch Surg       Date:  2012-06-13       Impact factor: 3.445

7.  Endoscopic retrograde cholangiopancreatography associated pancreatitis: A 15-year review.

Authors:  Kevin E Woods; Field F Willingham
Journal:  World J Gastrointest Endosc       Date:  2010-05-16

Review 8.  Early successes and late failures in the prevention of post endoscopic retrograde cholangiopancreatography.

Authors:  John G Lieb; Peter V Draganov
Journal:  World J Gastroenterol       Date:  2007-07-14       Impact factor: 5.742

Review 9.  Treatment of gastrointestinal sphincters spasms with botulinum toxin A.

Authors:  Giuseppe Brisinda; Nicola Sivestrini; Giuseppe Bianco; Giorgio Maria
Journal:  Toxins (Basel)       Date:  2015-05-29       Impact factor: 4.546

Review 10.  Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: What We Already Know.

Authors:  Adham E Obeidat; Ratib Mahfouz; Gabriel Monti; Landon Kozai; Mohammad Darweesh; Mahmoud M Mansour; Ahmad Alqam; David Hernandez
Journal:  Cureus       Date:  2022-01-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.